Logo

Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rheumatology

Share this
Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rheumatology

Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rheumatology

Shots:

  • The P-IV (MIRROR) randomized controlled trial evaluates Krystexxa + methotrexate vs Krystexxa + PBO in a ratio (2:1) in 152 patients with uncontrolled gout
  • The 1EPs of the study were the proportion of serum uric acid (sUA) responders @6mos. (20-24wks.) & the 2EPs included the proportion of sUA responders @12mos. (48-52wks.)
  • The results showed a ≥30% point increase in patient response rate @6mos., patients achieved the primary efficacy EPs (71% vs 39%), reduction in infusion reactions from 31% to 4% with no new safety signals., 20%-point increase in the complete resolution of 1 tophus @24wks. (35% vs 14%), 76% had investigator-identified tophi, and all experienced 1 gout flare in the prior year

Ref: Horizon | Image: Horizon

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions